Morgan Stanley’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-542,722
| Closed | -$120M | – | 8326 |
|
|
2025
Q4 | $120M | Buy |
542,722
+164,538
| +44% | +$26.6M | 0.01% | 1288 |
|
|
2025
Q3 | $36.2M | Sell |
378,184
-505,231
| -57% | -$32.2M | ﹤0.01% | 2304 |
|
|
2025
Q2 | $43M | Buy |
883,415
+875,198
| +10,651% | +$21M | ﹤0.01% | 2062 |
|
|
2025
Q1 | $177K | Buy |
8,217
+5,787
| +238% | +$129K | ﹤0.01% | 5781 |
|
|
2024
Q4 | $65.3K | Buy |
2,430
+2,261
| +1,338% | +$36.7K | ﹤0.01% | 6206 |
|
|
2024
Q3 | $1.82K | Hold |
169
| – | – | ﹤0.01% | 7149 |
|
|
2024
Q2 | $2.02K | Sell |
169
-611
| -78% | -$8.36K | ﹤0.01% | 7065 |
|
|
2024
Q1 | $14.3K | Sell |
780
-250
| -24% | -$3.59K | ﹤0.01% | 6577 |
|
|
2023
Q4 | $16.4K | Sell |
1,030
-8,400
| -89% | -$135K | ﹤0.01% | 6496 |
|
|
2023
Q3 | $178K | Sell |
9,430
-12,725
| -57% | -$250K | ﹤0.01% | 5639 |
|
|
2023
Q2 | $501K | Buy |
22,155
+9,380
| +73% | +$220K | ﹤0.01% | 5211 |
|
|
2023
Q1 | $324K | Buy |
12,775
+12,700
| +16,933% | +$360K | ﹤0.01% | 5484 |
|
|
2022
Q4 | $1.13K | Hold |
75
| – | – | ﹤0.01% | 7455 |
|
|
2022
Q3 | $1K | Hold |
75
| – | – | ﹤0.01% | 7548 |
|
|
2022
Q2 | $1K | Sell |
75
-50
| -40% | -$618 | ﹤0.01% | 7663 |
|
|
2022
Q1 | $2K | Buy |
125
+41
| +49% | +$695 | ﹤0.01% | 7727 |
|
|
2021
Q4 | $2K | Sell |
84
-271
| -76% | -$8.44K | ﹤0.01% | 7784 |
|
|
2021
Q3 | $16K | Buy |
355
+208
| +141% | +$7.9K | ﹤0.01% | 7171 |
|
|
2021
Q2 | $6K | Buy |
147
+57
| +63% | +$2.41K | ﹤0.01% | 7337 |
|
|
2021
Q1 | $5K | Sell |
90
-1,309
| -94% | -$64.6K | ﹤0.01% | 7094 |
|
|
2020
Q4 | $56K | Buy |
1,399
+1,236
| +758% | +$61.5K | ﹤0.01% | 6126 |
|
|
2020
Q3 | $9K | Sell |
163
-353
| -68% | -$24.9K | ﹤0.01% | 6296 |
|
|
2020
Q2 | $38K | Buy |
516
+514
| +25,700% | +$33.3K | ﹤0.01% | 5769 |
|
|
2020
Q1 | $0 | Sell |
2
-70
| -97% | -$4.19K | ﹤0.01% | 6573 |
|
|
2019
Q4 | $5K | Buy |
72
+64
| +800% | +$2.93K | ﹤0.01% | 6392 |
|
|
2019
Q3 | $0 | Sell |
8
-45
| -85% | -$1.51K | ﹤0.01% | 6642 |
|
|
2019
Q2 | $2K | Buy |
53
+8
| +18% | +$332 | ﹤0.01% | 6453 |
|
|
2019
Q1 | $2K | Sell |
45
-162
| -78% | -$8.88K | ﹤0.01% | 6445 |
|
|
2018
Q4 | $10K | Sell |
207
-470
| -69% | -$33.5K | ﹤0.01% | 6158 |
|
|
2018
Q3 | $60K | Sell |
677
-621
| -48% | -$54.8K | ﹤0.01% | 5826 |
|
|
2018
Q2 | $135K | Sell |
1,298
-1,407
| -52% | -$133K | ﹤0.01% | 5664 |
|
|
2018
Q1 | $216K | Buy |
2,705
+1,734
| +179% | +$237K | ﹤0.01% | 5436 |
|
|
2017
Q4 | $132K | Buy |
971
+787
| +428% | +$119K | ﹤0.01% | 5552 |
|
|
2017
Q3 | $30K | Sell |
184
-653
| -78% | -$92.9K | ﹤0.01% | 5927 |
|
|
2017
Q2 | $125K | Sell |
837
-95
| -10% | -$13.1K | ﹤0.01% | 5545 |
|
|
2017
Q1 | $145K | Sell |
932
-1,030
| -52% | -$181K | ﹤0.01% | 5466 |
|
|
2016
Q4 | $408K | Buy |
1,962
+1,779
| +972% | +$370K | ﹤0.01% | 5043 |
|
|
2016
Q3 | $42K | Buy |
183
+86
| +89% | +$19.9K | ﹤0.01% | 5655 |
|
|
2016
Q2 | $20K | Sell |
97
-5
| -5% | -$1.21K | ﹤0.01% | 5848 |
|
|
2016
Q1 | $25K | Sell |
102
-1
| -1% | -$230 | ﹤0.01% | 5846 |
|
|
2015
Q4 | $36K | Sell |
103
-29
| -22% | -$8.71K | ﹤0.01% | 5835 |
|
|
2015
Q3 | $33K | Sell |
132
-3
| -2% | -$858 | ﹤0.01% | 5877 |
|
|
2015
Q2 | $38K | Buy |
+135
| New | +$41.5K | ﹤0.01% | 5945 |
|
Morgan Stanley's CDTX Position: Q1 2026 in Review
Morgan Stanley sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 542,722 shares — an estimated $120M sold.
Morgan Stanley first reported a position in CDTX in Q2 2015 and held it in 43 quarters. The position peaked at $120M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Morgan Stanley reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Morgan Stanley sold 542,722 Cidara Therapeutics shares in Q1 2026, an estimated $120M.
- Morgan Stanley first reported a position in Cidara Therapeutics in Q2 2015 and held it in 43 quarters.
- Morgan Stanley's Cidara Therapeutics position peaked at $120M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.